Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity
NCT01078636 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1), to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). ADNI-GO seeks to define and characterize the mildest symptomatic phase of AD, referred to in this study as early amnestic MCI (EMCI). This information will aid in the early detection of AD, and in measuring the effectiveness of treatments in future clinical trials.
Conditions Studied
Study Locations (20)
California
- University of California, Irvine — Irvine
- University of California, Irvine - BIC — Irvine
- University of Southern California — Los Angeles
- University of California, Los Angeles — Los Angeles
- University of California, Davis — Martinez
- Stanford University — Palo Alto
- University of California, San Diego — San Diego
- University of California, San Francisco — San Francisco
Florida
- Mayo Clinic, Jacksonville — Jacksonville
- Wien Center — Miami Beach
- Premiere Research Institute — West Palm Beach
Arizona
- Banner Alzheimer's Institute — Phoenix
- Banner Sun Health Research Institute — Sun City
District of Columbia
- Georgetown University — Washington D.C.
- Howard University — Washington D.C.
Illinois
- Northwestern University — Chicago
- Rush University Medical Center — Chicago
Alabama
- University of Alabama at Birmingham — Birmingham
Connecticut
- Yale University School of Medicine — New Haven
Georgia
- Emory University — Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 342 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-10 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01078636
The ClinicalTrials.gov registry entry for NCT01078636 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 342 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alzheimer's Disease Cooperative Study (ADCS), which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT01078636 reports 20 study locations spanning 8 distinct geographic areas — top geographies include California, Florida, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT01078636 about?
NCT01078636 is a clinical study titled "Alzheimer's Disease Neuroimaging Initiative Grand Opportunity". The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1), to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (A...
What is the current status of trial NCT01078636?
This trial is currently completed. The enrollment target is 342 participants. The study started on 2010-04. Estimated completion is 2012-10.
What conditions does trial NCT01078636 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment, Alzheimer's Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT01078636?
This trial is sponsored by Alzheimer's Disease Cooperative Study (ADCS), which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT01078636 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.